Sanofi has entered a licensing agreement with clinical-stage biotech companies RadioMedix and Orano Med to commercialize lead-212 (Pb-212) DOTAMTATE, a radioligand therapy for neuroendocrine tumors (NETs).
Under the terms of the deal, U.S.-based RadioMedix and France-based Orano Med will receive an upfront payment of $110 million and up to $243 million in sales milestones and be eligible for tiered royalties, Sanofi said.
Pb-212 DOTAMTATE (AlphaMedix) is in late-stage development for the treatment of adult patients with unresectable or metastatic, progressive somatostatin-receptor-expressing NETs. The targeted alpha therapy consists of a somatostatin receptor-targeting peptide complex radiolabeled with lead-212, which generates alpha particles that kill cancer cells at tumor sites.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
